| SC 13G/A | 2017-02-14 | ARMISTICE CAPITAL, LLC | Aegerion Pharmaceuticals, Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2017-02-14 | PUTNAM INVESTMENTS LLC | Aegerion Pharmaceuticals, Inc. | - | - | EDGAR |
| SC 13G/A | 2017-02-08 | INTEGRATED CORE STRATEGIES (US) LLC | Aegerion Pharmaceuticals, Inc. | - | 0.0% | EDGAR |
| SC 13G/A | 2017-01-31 | Athyrium Opportunities II Acquisition LP | Aegerion Pharmaceuticals, Inc. | - | - | EDGAR |
| SC 13G/A | 2016-12-12 | FMR LLC | Aegerion Pharmaceuticals, Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2016-12-05 | SCOPIA CAPITAL MANAGEMENT LP | Aegerion Pharmaceuticals, Inc. | 0 | 0.0% | EDGAR |
| SC 13D/A | 2016-12-01 | Broadfin Capital, LLC | Aegerion Pharmaceuticals, Inc. | 0 | 0.0% | EDGAR |
| SC 13D/A | 2016-11-30 | Sarissa Capital Management LP | Aegerion Pharmaceuticals, Inc. | 0 | 0.0% | EDGAR |
| SC 13G | 2016-11-16 | ARMISTICE CAPITAL, LLC | Aegerion Pharmaceuticals, Inc. | 1,664,000 | 5.6% | EDGAR |
| SC 13D/A | 2016-09-13 | Broadfin Capital, LLC | Aegerion Pharmaceuticals, Inc. | 4,286,291 | 14.5% | EDGAR |
| SC 13G/A | 2016-07-08 | BlackRock Inc. | Aegerion Pharmaceuticals, Inc. | 1,158,167 | 3.9% | EDGAR |
| SC 13D | 2016-06-24 | Aegerion Pharmaceuticals, Inc. | QLT INC/BC | 13,109,202 | 24.8% | EDGAR |
| SC 13D | 2016-06-23 | QLT INC/BC | Aegerion Pharmaceuticals, Inc. | - | 22.6% | EDGAR |
| SC 13D | 2016-06-22 | Broadfin Capital, LLC | Aegerion Pharmaceuticals, Inc. | 4,010,291 | 13.6% | EDGAR |
| SC 13D/A | 2016-06-16 | Sarissa Capital Management LP | Aegerion Pharmaceuticals, Inc. | 2,649,000 | 9.0% | EDGAR |
| SC 13G/A | 2016-05-10 | FMR LLC | Aegerion Pharmaceuticals, Inc. | 2,859,929 | 9.7% | EDGAR |
| SC 13D/A | 2016-03-22 | Sarissa Capital Management LP | Aegerion Pharmaceuticals, Inc. | - | - | EDGAR |
| SC 13G | 2016-03-18 | Athyrium Opportunities II Acquisition LP | Aegerion Pharmaceuticals, Inc. | 1,649,084 | 5.3% | EDGAR |
| SC 13G | 2016-03-07 | ARMISTICE CAPITAL, LLC | Aegerion Pharmaceuticals, Inc. | 1,502,000 | 5.2% | EDGAR |
| SC 13G/A | 2016-02-16 | Point72 Asset Management, L.P. | Aegerion Pharmaceuticals, Inc. | 0 | 0.0% | EDGAR |